Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Minal A. Barve

Oncology | Internal Medicine
8196 Walnut Hill Lane, Suite 100, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
32 Years of Experience
Advanced in Non-Small Cell Lung Cancer (NSCLC)
8196 Walnut Hill Lane, Suite 100, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Minal Barve is an Oncologist and an Internal Medicine provider in Dallas, Texas. Dr. Barve has been practicing medicine for over 32 years and is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Ovarian Cancer, Non-Hodgkin Lymphoma, Follicular Lymphoma, and Chronic Myelogenous Leukemia (CML).

Her clinical research consists of co-authoring 51 peer reviewed articles and participating in 37 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles and participated in 14 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Graduate Institution
Dr. Panjabrao Alias Bhausaheb Deshmukh Memorial Medical College, 1993
Residency
Internal Medicine, Presbyterian Hospital of Dallas
Specialties
Oncology
Internal Medicine
Licenses
Internal Medicine in TX
Board Certifications
American Board Of Internal Medicine
Fellowships
Medical Oncology, Baylor University Hospital
Medical Oncology, Baylor University Medical Center
Hospital Affiliations
Texas Health Presbyterian Hospital Dallas
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
8196 Walnut Hill Lane, Suite 100, Dallas, TX 75231

Additional Areas of Focus

Dr. Barve has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

37 Clinical Trials

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 03, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects
A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: INCAGN01876, Nivolumab, Ipilimumab
Study Phase: Phase 1/Phase 2
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Enrollment Status: Completed
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Docetaxel, GSK3359609, Ipilimumab, Niraparib, Dostarlimab, Cobolimab
Study Phase: Phase 2
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Biological
Study Drug: Vigil™
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Biological
Study Drugs: SRK-181, Anti-PD-(L)1 Antibody Therapy
Study Phase: Phase 1
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drug: TH1902
Study Phase: Phase 1
A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Enrollment Status: Enrolling_by_invitation
Publish Date: February 04, 2025
Intervention Type: Drug, Biological
Study Drugs: SV-BR-1-GM, INCMGA00012, Low Dose Cyclophosphamide, Interferon Inoculation, Epacadosta
Study Phase: Phase 1/Phase 2
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: AGEN2373, Botensilimab
Study Phase: Phase 1
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: Pamiparib, Temozolomide
Study Phase: Phase 1
Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drug: NBF-006
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Terminated
Publish Date: March 15, 2024
Intervention Type: Biological
Study Drug: XMT-1592
Study Phase: Phase 1
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Intravenously as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Intravenously as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drugs: CPI-006 Anti-CD73 Antibody, Ciforadenant, Pembrolizumab
Study Phase: Phase 1
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: October 23, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Enrollment Status: Completed
Publish Date: April 05, 2023
Intervention Type: Drug, Biological
Study Drugs: Vigil Tumor Cells, Atezolizumab
Study Phase: Phase 2
A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sarcoma Treated With Vigil Versus Gemcitabine and Docetaxel and to Determine Safety Profile of Vigil in Combination With Irinotecan and Temozolomide.
A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sarcoma Treated With Vigil Versus Gemcitabine and Docetaxel and to Determine Safety Profile of Vigil in Combination With Irinotecan and Temozolomide.
Enrollment Status: Completed
Publish Date: December 22, 2022
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
Enrollment Status: Terminated
Publish Date: August 03, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors
A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors
Enrollment Status: Terminated
Publish Date: December 22, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: November 13, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: September 27, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: July 31, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 34 Less Clinical Trials

50 Total Publications

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma.
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 03, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. David E. Gerber
Oncology | Hematology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. David E. Gerber
Oncology | Hematology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, Dermatology, 
Dallas, TX 
 (15.6 miles away)
214-645-2400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Gerber is an Oncologist and a Hematologist in Dallas, Texas. Dr. Gerber is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Endoscopy.

John D. Minna
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. John D. Minna
Oncology | Hematology Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. John D. Minna
Oncology | Hematology Oncology
5323 Harry Hines Blvd, 
Dallas, TX 
 (16.0 miles away)
214-645-8600
Languages Spoken:
English
See accepted insurances

John Minna is an Oncologist and a Hematologist Oncology provider in Dallas, Texas. Dr. Minna is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC).

Jonathan E. Dowell
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Jonathan E. Dowell
Hematology Oncology | Hematology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Jonathan E. Dowell
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (15.5 miles away)
214-645-2700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Dowell is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Dowell is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and EGFR Positive Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barve's expertise for a condition
ConditionClose
      View All 15 Advanced Conditions
      View All 82 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile